《华盛顿邮报》强调，秃鹫锐减与养殖户给牛滥用药物有着密切联系，这一由人类活动引发的连锁影响耗时十年才得以被确认。美国兽医病理学 家J·林赛·奥克斯领导的研究团队曾对白背秃鹫尸体进行尸检。研究团队发现，85%的死亡秃鹫患有内脏痛风，这种疾病通常发生在鸟类肾功能衰 竭时。双氯芬酸就是导致秃鹫肾衰竭死亡的"凶手"，该药物被广泛用于治疗病牛的疼痛和炎症。 报道称，印度正采取多种补救措施，政府已禁止将部分对秃鹫有害的化学物质用于畜牧养殖，并着手建立更完善的鸟类保护项目。当地的环保主 义者甚至设立数家"秃鹫餐厅"，提供可供秃鹫安全食用的牛尸。印度《前线》杂志警告，印度部分野生动物的消失已超越单一的生物多样性危 机，演变为一场人类活动直接导致的公共卫生危机，为人类自身的生存与发展敲响了警钟。（苑基荣） 印度《脚踏实地》杂志网站援引印度野生动物研究所的评估称，秃鹫已从72%的历史筑巢地消失。中央邦和拉贾斯坦邦合计拥有印度近2/3的秃鹫 巢穴，其中超过60%位于保护区内。生物学家记录的425个秃鹫历史筑巢地中仅有120个仍在使用。报道称，1992年至2007年，印度秃鹫数大量减 少，长嘴秃鹫、细嘴秃鹫和白背秃鹫这3个物种的数量 ...

Core Viewpoint - The recent failure of Organon's candidate drug OG-6219 in Phase II clinical trials highlights the challenges in developing effective treatments for endometriosis, a condition affecting approximately 190 million women globally, with significant implications for the company's innovation pipeline and the broader market for pain management in women’s health [1][2][9]. Group 1: Market Demand and Supply - Endometriosis is a high-prevalence disease that causes severe pelvic pain and can lead to infertility, affecting about 1 in 10 women of reproductive age [1]. - Despite the significant treatment demand, there is a scarcity of new drugs, primarily due to the unclear underlying mechanisms of the disease, which complicates research and development [2][4]. - The complexity of individual patient factors, such as hormonal levels and inflammation, further complicates the development of effective treatments, leading to a low conversion rate for new mechanism drugs [2][4]. Group 2: Challenges in Drug Development - Existing treatments, such as NSAIDs, provide temporary relief but do not address the root cause of endometriosis, creating a high barrier for new drugs to demonstrate superior efficacy [2][3]. - High costs and side effects associated with approved drugs, such as AbbVie’s Orilissa and Pfizer’s Myfembree, have limited market acceptance [3][4]. - The failure of Organon’s OG-6219, which was expected to be a breakthrough treatment, underscores the difficulties in drug development within this therapeutic area [7][8]. Group 3: Organon's Position - Organon, formed from Merck's spinoff, aimed to innovate in women's health through acquisitions, including the purchase of Forendo Pharma for $750 million, which included OG-6219 [6]. - The failure of OG-6219 has significantly impacted Organon's innovation pipeline, leaving it with limited options for future development in endometriosis treatment [7][8]. - Despite the setback, Organon has expressed intentions to explore new treatment options for endometriosis, although the high difficulty and long timelines in this field pose significant challenges [8][12]. Group 4: Future Outlook - While the failure of OG-6219 is disappointing, the potential for innovation in endometriosis treatment remains, with ongoing research into alternative pathways and new compounds [10][11]. - Current research efforts are primarily focused on traditional pathways, but there are emerging explorations into novel approaches, such as cannabinoid therapies and inflammation-targeting strategies [11]. - A significant shift in the treatment landscape may require breakthroughs in technology and a renewed commitment from the industry to address the unmet medical needs of millions of women suffering from endometriosis [12].